Breaking Finance News

RBC Capital Markets disclosed ObsEva (NDAQ:OBSV), hiking its price target to $22.00 earlier today

Having a price of $7.05, ObsEva (NDAQ:OBSV) traded 0.36% higher on the day. With the last stock price down -32.72% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. OBSV has recorded a 50-day average of $6.96 and a two hundred day average of $10.41. Trade Volume was down over the average, with 4,982 shares of OBSV changing hands under the typical 11,875

Indicating a possible upside of 2.12%, RBC Capital Markets raised the target price of ObsEva (NDAQ:OBSV) to $22.00

On 6/29/2017, H.C. Wainwright released a statement about ObsEva (NDAQ:OBSV) upped the target price from $0.00 to $27.00 that suggested an upside of 2.74%.

Recent Performance Chart

ObsEva (NDAQ:OBSV)

ObsEva has with a one year low of $6.77 and a one year high of $14.18 and has a market capitalization of $0.

General Company Details For ObsEva (NDAQ:OBSV)

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women's reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.